Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

Panagiotis Konstantinopoulos; Jae-Weon Kim; Gilles Freyer; Jung-Yun Lee; Lydia Gaba; Rachel Grisham; Nicoletta Colombo; Xiaohua Wu; Jalid Sehouli; Felipe Cruz; David Cibula; Bradley Monk; Gitte-Bettina Nyvang; Michael Friedlander; Domenica Lorusso; Els Van Nieuwenhuysen; Rosalind Glasspool; Christian Marth; Patsy Hinson; Monica Zuradelli; Craig Wang; Faye Su; Michelle Miller; Ursula Matulonis; Antonio González-Martín

doi:10.1016/j.ygyno.2024.07.024

$Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial$

Journal article

Peer reviewed

Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

Panagiotis Konstantinopoulos, Jae-Weon Kim, Gilles Freyer, Jung-Yun Lee, Lydia Gaba, Rachel Grisham, Nicoletta Colombo, Xiaohua Wu, Jalid Sehouli, Felipe Cruz, …

Gynecologic oncology, Vol.190, pp.S12-S12

11/2024

DOI: https://doi.org/10.1016/j.ygyno.2024.07.024

Metrics

7 Record Views

Details

Title: Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
Creators: Panagiotis Konstantinopoulos - Dana-Farber Cancer Institute
Jae-Weon Kim - Seoul National University
Gilles Freyer - Hospices Civils de Lyon
Jung-Yun Lee - Yonsei University Health System
Lydia Gaba - Hospital Clínic de Barcelona
Rachel Grisham - Memorial Sloan Kettering Cancer Center
Nicoletta Colombo - Mylan
Xiaohua Wu - Fudan University
Jalid Sehouli - Charité - Universitätsmedizin Berlin
Felipe Cruz - Instituto Brasileiro de Controle do Câncer
David Cibula - General University Hospital in Prague
Bradley Monk - Creighton University
Gitte-Bettina Nyvang - Odense University Hospital
Michael Friedlander - Prince of Wales Hospital/Clinical School, University of NSW, Sydney, Australia
Domenica Lorusso - Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
Els Van Nieuwenhuysen - Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Rosalind Glasspool - University of Glasgow
Christian Marth - Universität Innsbruck
Patsy Hinson - Ovarian Cancer Research Alliance
Monica Zuradelli - Novartis
Craig Wang - Novartis
Faye Su - Novartis Pharmaceuticals Corporation East Hanover, NJ, United States
Michelle Miller - Novartis Pharmaceuticals Corporation East Hanover, NJ, United States
Ursula Matulonis - Dana-Farber Cancer Institute
Antonio González-Martín - Clinica Universidad de Navarra
Publication Details: Gynecologic oncology, Vol.190, pp.S12-S12
Publisher: Elsevier Inc
Identifiers: 991006118331402656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

Related links

Metrics

Details